TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval
(Alliance News) - AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab. Read More